Michele Cavo, MD | Authors

Upfront ASCT Still Best Option in Newly Diagnosed Multiple Myeloma

June 23, 2016

In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.